Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 39.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Clever Leaves Holdings was 39.90% per year. The lowest was 16.40% per year. And the median was 28.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Clever Leaves Holdings 3-Year EBITDA Growth Rate Related Terms
CLVRW vs CNNC, CLSH, PRFX: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clever Leaves Holdings 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Clever Leaves Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 39.90% mean?
Clever Leaves Holdings (CLVRW) has a 3-Year EBITDA Growth Rate of 39.90% as of Dec. 2023. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Clever Leaves Holdings and its competitors. This is 42% above median its historical median of 28.15. Over the past decade, Clever Leaves Holdings' 3-Year EBITDA Growth Rate has ranged from 16.40 to 39.90.
Is Clever Leaves Holdings' 3-Year EBITDA Growth Rate too high?
Clever Leaves Holdings' current 3-Year EBITDA Growth Rate of 39.90% is 42% above median its 10-year median of 28.15. Over the past 10 years, this metric has ranged from a low of 16.40 to a high of 39.90. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Clever Leaves Holdings' value of 39.90% is 348.3% above this industry median. Overall, Clever Leaves Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Clever Leaves Holdings' 3-Year EBITDA Growth Rate compare to CNNC and CLSH?
Clever Leaves Holdings' 3-Year EBITDA Growth Rate of 39.90% can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Clever Leaves Holdings' value of 39.90% is 348.3% above this benchmark. Historically, Clever Leaves Holdings' own 3-Year EBITDA Growth Rate has ranged from 16.40 to 39.90 over the past decade. While the company's 10-year median is 28.15 vs. the industry median of 8.90, Clever Leaves Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clever Leaves Holdings's current 3-Year EBITDA Growth Rate of 39.90% is 348.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Clever Leaves Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clever Leaves Holdings's current 3-Year EBITDA Growth Rate is 39.90%, which is 42% above median its own 10-year median of 28.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clever Leaves Holdings stock overvalued right now?
Clever Leaves Holdings (CLVRW) has a current 3-Year EBITDA Growth Rate of 39.90%. The current 3-Year EBITDA Growth Rate is 39.90%, which is 42% above median its 10-year median of 28.15 and 348.3% above the Drug Manufacturers industry median of 8.90. Clever Leaves Holdings' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Clever Leaves Holdings (CLVRW), the current 3-Year EBITDA Growth Rate is 39.90% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments namely, the Cannabinoid segment which is comprised of the company's cultivation, extraction, and commercialization of cannabinoid products; and the Non-Cannabinoid operating segment which generates maximum revenue and is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.
12GF Score
Get the complete analysis for CLVRW
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVRW has been successfully added to your 
